Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 3635-3640

  Roberts, Jason A ^a   Field, Jonathan ^b   Visser, Adam ^b   Whitbread, Rosemary ^b   Tallot, Mandy ^b   Lipman, Jeffrey ^a   Kirkpatrick, Carl M J ^c  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DIAFILTRATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; KIDNEY INJURY; MALE; MINIMUM INHIBITORY CONCENTRATION; PLASMA HALF LIFE; POPULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIMULATION; THERAPY EFFECT;

ACUTE KIDNEY INJURY; AGED; AGED, 80 AND OVER; CRITICAL ILLNESS; FEMALE; FILTRATION; GENTAMICINS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 77956115684     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00222-10     Document Type: Article

References (20)

1. Baldwin, I., T. Naka, B. Koch, N. Fealy, and R. Bellomo. 2007. A pilot randomised controlled comparison of continuous veno-venous haemofiltration and extended daily dialysis with filtration: effect on small solutes and acid-base balance. Intensive Care Med. 33:830-835. (Pubitemid 46675330)
2. Beal, S. L., and L. B. Sheiner. 1998. NONMEM user guides (I to VIII). University of California at San Francisco, San Francisco, CA.
3. Bearden, D. T., and K. A. Rodvold. 2000. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin. Pharmacokinet. 38:415-426.
4. Begg, E. J., M. L. Barclay, and S. B. Duffull. 1995. A suggested approach to once-daily aminoglycoside dosing. Br. J. Clin. Pharmacol. 39:605-609.
5. Chertow, G. M., E. M. Levy, K. E. Hammermeister, F. Grover, and J. Daley. 1998. Independent association between acute renal failure and mortality following cardiac surgery. Am. J. Med. 104:343-348.
6. Choi, G., C. D. Gomersall, Q. Tian, G. M. Joynt, R. C. Freebairn, and J. Lipman. 2009. Principles of antibacterial dosing in continuous renal replacement therapy. Crit. Care Med. 37:2268-2282.
7. Czock, D., C. Husig-Linde, A. Langhoff, T. Schopke, C. Hafer, K. de Groot, S. Swoboda, E. Kuse, H. Haller, D. Fliser, F. Keller, and J. T. Kielstein. 2006. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin. J. Am. Soc. Nephrol. 1:1263-1268.
8. Dasta, J. F., and D. K. Armstrong. 1988. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit. Care Med. 16:327-330.
9. Janmahasatian, S., S. B. Duffull, S. Ash, L. C. Ward, N. M. Byrne, and B. Green. 2005. Quantification of lean bodyweight. Clin. Pharmacokinet. 44: 1051-1065.
10. Kielstein, J. T., D. Czock, T. Schopke, C. Hafer, S. M. Bode-Boger, E. Kuse, F. Keller, and D. Fliser. 2006. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit. Care Med. 34:51-56.
11. Levy, E. M., C. M. Viscoli, and R. I. Horwitz. 1996. The effect of acute renal failure on mortality. A cohort analysis. JAMA 275:1489-1494.
12. Marik, P. E. 1993. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth. Intensive Care 21:172-173. (Pubitemid 23132762)
13. Marik, P. E., J. Lipman, S. Kobilski, and J. Scribante. 1991. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J. Antimicrob. Chemother. 28:753-764.
14. Matthews, I., C. Kirkpatrick, and N. Holford. 2004. Quantitative justification for target concentration intervention-parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br. J. Clin. Pharmacol. 58:8-19.
15. Parke, J., N. H. Holford, and B. G. Charles. 1999. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput. Methods Programs Biomed. 59:19-29.
16. Ricci, Z., and C. Ronco. 2008. Dose and efficiency of renal replacement therapy: continuous renal replacement therapy versus intermittent hemodialysis versus slow extended daily dialysis. Crit. Care Med. 36:S229-S237.
17. Roberts, J. A., and J. Lipman. 2006. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin. Pharmacokinet. 45:755-773.
18. Teigen, M. M., S. Duffull, L. Dang, and D. W. Johnson. 2006. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J. Clin. Pharmacol. 46:1259-1267.
19. Triginer, C., I. Izquierdo, R. Fernandez, J. Rello, J. Torrent, S. Benito, and A. Net. 1990. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med. 16:303-306. (Pubitemid 20253465)
20. Uchino, S., J. A. Kellum, R. Bellomo, G. S. Doig, H. Morimatsu, S. Morgera, M. Schetz, I. Tan, C. Bouman, E. Macedo, N. Gibney, A. Tolwani, and C. Ronco. 2005. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294:813-818. (Pubitemid 41175724)